Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial

Journal of the National Cancer Institute

Volumn 100, Issue 2, 2008, Pages 121-133

  Francis, Prudence ^a,b,c   Crown, John ^d   Di Leo, Angelo ^e   Buyse, Marc ^f   Balil, Ana ^g,h   Andersson, Michael ⁱ   Nordenskjöld, Bo ^j   Lang, Istvan ^k   Jakesz, Raimund ^l   Vorobiof, Daniel ^m   Gutiérrez, Jorge ⁿ   Van Hazel, Guy ^o   Dolci, Stella ^p   Jamin, Sophie ^p   Bendahmane, Belguendouz ^q   Gelber, Richard D ^r   Goldhirsch, Aron ^s   Castiglione Gertsch, Monica ^t   Piccart Gebhart, Martine ^p  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Australian New Zealand Breast Cancer Trials Group   (Australia)

^c International Breast Cancer Study Group   (Switzerland)

^d All Ireland Cooperative Oncology Research Group   (Ireland)

^e HOSPITAL OF PRATO   (Italy)

^f INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^g Grupo Español de Investigación en Cáncer de Mama   (Spain)

^h HOSPITAL ARNAU DE VILANOVA   (Spain)

ⁱ Danish Breast Cancer Cooperative Group   (Denmark)

^j LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^k NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m Sandton Oncology Centre   (South Africa)

ⁿ CLÍNICA LAS CONDES   (Chile)

^o Mount Hospital   (Australia)

^p JULES BORDET INSTITUTE   (Belgium)

^q SANOFI   (France)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^t UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; STEROID; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CMF REGIMEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAXOID; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; AMENORRHEA; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DEATH; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; INFECTION; LOG RANK TEST; LYMPH NODE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROSENSORY TOXICITY; NEUTROPENIC SEPSIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SEPSIS; SKIN TOXICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MASTECTOMY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TAXOIDS; TREATMENT OUTCOME;

EID: 38449108413     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm287     Document Type: Article

References (29)

1. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
2. Rossi A, Bonadonna G, Valagussa P, Veronesi U. Multimodal treatment in operable breast cancer: five year results of the CMF program. Br Med J. 1981;282:1427-1431.
3. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2-10.
4. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non-responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483-1496.
5. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991;9:2134-2140.
6. Engelsman E, Klijn JC, Rubens RD, et al. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC Breast Cancer Cooperative Group phase III trial. Eur J Cancer. 1991;27:966-970.
7. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13:2879-2885.
8. Valero V, Holmes F, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13:2886-2894.
9. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-2354.
10. Misset JL, Dieras V, Griua G, et al. Dose finding study of docetaxel and doxorubicin in first line treatment of patients with metastatic breast cancer. Ann Oncol. 1999;10:553-560.
11. Di Leo A, Crown J, Nogaret JM, et al. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol. 2000;11:169-175.
12. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.
13. Chi GYH. Multiple testings: multiple comparisons and multiple end-points. Drug Inf J. 1998;32:1347-1362.
14. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
15. Roche H, Fumoleau P, Spielman M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24:5664-5671.
16. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851-1862.
17. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second line treatment of advanced breast cancer. J Clin Oncol. 2006;24:4963-4970.
18. Norton L, Simon R. Predicting the course of Gompertzian growth. Nature. 1976;264:542-545.
19. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163-169.
20. Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676-2685.
21. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. J Clin Oncol. 2004;22:2587-2593.
22. Zambetti M, Giacobone A, Terenziani M, et al. Sequential adriamycin and CMF in metastatic breast cancer. Oncologist. 1997;2:223-227.
23. Evans TRJ, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol. 2005;23:2988-2995.
24. Goldstein LJ, O'Neill A, Sparano J, et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol. 2005;23(16S):7s.
25. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381-5387.
26. Duric V, Francis P, Simard-Lebrun J, et al. Preferences for adjuvant chemotherapy in early breast cancer: the benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile. J Clin Oncol. 2007;25(18S):329s.
27. Duric V, Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol. 2001;2(11):691-697.
28. Citron M, Berry D, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-1439.
29. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high risk node negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Paper presented at: The 28th San Antonio Breast Cancer Symposium; December 8, 2005; San Antonio, TX. Abstract 48